Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Total Debt (2018 - 2023)

Historic Total Debt for X4 Pharmaceuticals (XFOR) over the last 5 years, with Q2 2023 value amounting to $764000.0.

  • X4 Pharmaceuticals' Total Debt fell 9112.35% to $764000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $764000.0, marking a year-over-year decrease of 9112.35%. This contributed to the annual value of $1.3 million for FY2022, which is 6540.88% up from last year.
  • Per X4 Pharmaceuticals' latest filing, its Total Debt stood at $764000.0 for Q2 2023, which was down 9112.35% from $554000.0 recorded in Q1 2023.
  • Over the past 5 years, X4 Pharmaceuticals' Total Debt peaked at $26.3 million during Q2 2019, and registered a low of $554000.0 during Q1 2023.
  • In the last 4 years, X4 Pharmaceuticals' Total Debt had a median value of $2.4 million in 2022 and averaged $6.2 million.
  • In the last 5 years, X4 Pharmaceuticals' Total Debt skyrocketed by 200981.24% in 2022 and then tumbled by 9112.35% in 2023.
  • Over the past 4 years, X4 Pharmaceuticals' Total Debt (Quarter) stood at $26.3 million in 2019, then tumbled by 96.98% to $795000.0 in 2021, then skyrocketed by 65.41% to $1.3 million in 2022, then crashed by 41.9% to $764000.0 in 2023.
  • Its Total Debt stands at $764000.0 for Q2 2023, versus $554000.0 for Q1 2023 and $1.3 million for Q4 2022.